0
0
Read Time:8 Minute, 47 Second
The Epigenetics Market is Expected to Grow at a CAGR of 15.7% from 2024 to 2031 to Reach $6.33 Billion by 2031, According to Meticulous Research®.
The Epigenetics Market includes kits, reagents, instruments & accessories, software, and services. The growth of the epigenetics market is driven by the rising incidence of chronic diseases due to growth in the aging population, the increasing prevalence of cancer, rising pharmaceutical R&D expenditures, the increasing focus on epigenetics in drug discovery & development, and the declining costs of genome sequencing. The growing applications of epigenetics in non-oncology diseases and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the stakeholders in this market.
Here are the top 10 companies operating in the Epigenetics Market
Thermo Fisher Scientific Inc. (U.S.)
Founded in 1956 and headquartered in Massachusetts, U.S., Thermo Fisher offers products and services in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, government, and academic sectors. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment offers epigenetic products.
Thermo Fisher has a strong geographic presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa through its subsidiaries, R&D sites, and a strong distribution network. As of December 2022, the company had a headcount of 130,000 employees, of which 67,000 were employed in the Americas, 21,000 in Asia-Pacific, and 42,000 in Europe and the Middle East & Africa.
Incorporated in 1998 and headquartered in California, U.S., Illumina provides sequencing- and array-based genomic and genetic analysis solutions. The company operates through two reportable segments: Core Illumina and GRAIL. The Core Illumina segment offers various epigenetic solutions to simplify workflows and accelerate analysis.
Illumina provides its products to government laboratories, genomic research centers, academic institutions, hospitals, commercial molecular diagnostics laboratories, and pharmaceutical and consumer genomics companies. The company has manufacturing sites and laboratories in the U.S., Singapore, and the U.K.
Illumina distributes its products globally in North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa through its distributors. Some of its subsidiaries operating in the epigenetics market are Illumina GmbH (Germany), Illumina Australia Pty. Ltd. (Australia), Illumina UK, Ltd. (U.K.), Illumina Italy S.r.l. (Italy), Illumina Netherlands B.V. (Netherlands) and Illumina K.K. Japan (Japan).
PerkinElmer, Inc. (U.S.)
Founded in 1937 and headquartered in Massachusetts, U.S., PerkinElmer is a multinational company that offers products, solutions, and services for the life sciences, diagnostics, and applied markets. It operates through two reportable business segments: Discovery & Analytical Solutions and Diagnostics. Both these segments offer epigenetic products. In 2023, PerkinElmer’s life science and diagnostics spinoff rebranded as Revvity.
The company’s manufacturing and R&D facilities are located in several countries, including the U.S., China, Japan, and Germany. Furthermore, the company has a strong network of sales and marketing channels and service personnel in over 38 countries and sells its products and services in over 190 countries.
Founded in 1984 and headquartered in Venlo, Netherlands, Qiagen N.V. is one of the leading providers of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company offers its products through only one reportable segment and provides them in two major markets: Molecular Diagnostics and Life Sciences. The company categorized offerings under five product groups: Sample Technologies, Diagnostic Solutions, PCR/ Nucleic Acid Amplification, Genomics/NGS, and Others. The company offers epigenetic products under Sample Technologies, PCR/ Nucleic Acid Amplification, and Genomics/NGS product groups. Furthermore, the company offers these products to 500,000 customers in Molecular Diagnostics (human health) and Life Sciences (academic, research, pharma & biotech companies, and applied applications.
The company markets products in more than 130 countries across the globe. The company has facilities located in the U.S., China, Germany, Poland, the Philippines, Denmark, Romania, Spain, the U.K., and other countries. Furthermore, the company’s sales are handled by distributors and sales subsidiaries. It also sells products directly to customers. In the Americas, Europe, Asia, and Australia, the subsidiaries mainly take care of sales.
Pacific Biosciences of California, Inc. (U.S.)
Founded in 2004 and headquartered in California, U.S., Pacific Biosciences of California is a life science technology company that designs, develops, and manufactures advancing sequencing solutions that help researchers and scientists solve genetically complex problems in genomes, transcriptomes, and epigenomes areas. The company focuses on two core technologies: HiFi long-read sequencing technology and short read Sequencing by Binding (SBB) technology. Pacific Biosciences’ products address solutions to various applications, including plant and animal sciences, human germline sequencing, oncology, infectious disease and microbiology, gene therapy, and other emerging applications.
Pacific Biosciences operates through a single business segment and provides its products to various end users such as academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals, clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.
The company has a direct presence across the U.K., China, Japan, South Korea, Singapore, and the Middle East & Africa. The company has a global sales force and distribution partners in Asia and Australia, certain parts of Europe, the Middle East and Africa, and Latin America.
Meticulous Research in its latest publication on Epigenetics Market has predicted the growth of 15.7% during the forecast year 2024-2031.
Bio-Rad Laboratories, Inc. (U.S.)
Founded in 1952 and headquartered in California, U.S., Bio-Rad Laboratories, Inc. is a distributor and manufacturer of clinical diagnostics products and life science research. The company supplies and produces various systems and products for healthcare, analytical chemistry, and life sciences research. Bio-Rad Laboratories operates through two reportable segments: Clinical Diagnostics and Life Sciences, of which the Life Sciences segment provides epigenetic products.
The company has a direct distribution source in over 35 countries outside the U.S., including Afghanistan, France, Hong Kong, Japan, Korea, Iceland, Germany, Australia, Spain, the Netherlands, and South Africa.
10X Genomics, Inc. (U.S.)
Founded in 2012 and headquartered in California, U.S., 10X Genomics, Inc. is engaged in bringing advances in biomedicine to transform the treatment of diseases. Its product portfolio mainly comprises integrated solutions, including consumables, instruments, and software.
Furthermore, the company operates in a single reportable segment. It provides products that accelerate genetic discoveries with the help of high-resolution DNA sequencing technology, leading to a better understanding of biology and diseases.
The company’s customers are biomedical research institutes, pharmaceutical companies, and clinical centers, among others, in some major geographies globally, including the United States, Europe, the Middle East & Africa, and Asia-Pacific.
Through its manufacturing and sales operations, BD has a direct presence in the U.S., Brazil, Canada, China, France, Spain, the U.K., Germany, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Singapore, and the Netherlands. The R&D facilities of the company are in China, France, India, Ireland, the U.S., and Singapore. BD has a wide global distribution network and markets its products through independent distribution channels and directly to hospitals, healthcare institutions, and independent sales representatives.
Founded in 1668 and headquartered in Darmstadt, Germany, Merck is a healthcare and technology company. It operates globally through its three major business segments: Life Science, Healthcare, and Electronics. The Life Science segment is further sub-segmented into Research Solutions, Process Solutions, and Applied Solutions. The company offers epigenetic products through the Life Science segment. The company provides products to various end users, such as academic institutions, government labs, pharmaceutical companies, R&D, and biotech organizations.
Merck has a wide geographic presence in over 150 countries globally. As of December 2022, the company had 64,243 employees across Europe, North America, Asia-Pacific, Latin America, and the Middle East & Africa. The Life Science business segment has 52 manufacturing sites and over 100 distribution centers.
New England Biolabs (U.S.)
Founded in 1974 and headquartered in Massachusetts, U.S., New England Biolabs is engaged in developing, manufacturing, and marketing life science industry products. The company provides recombinant and native enzymes for genomic research. At the same time, restriction enzymes remain part of the core product portfolio, which includes products related to PCR, gene expression, sample preparation for next-generation sequencing, synthetic biology, glycobiology, epigenetics, and RNA analysis.
The company has over 100 scientists engaged in research in enzyme analysis and engineering, epigenetics, RNA biology, and parasitology. Due to this, the company has over 1,100 papers. The company also received ISO 14001, ISO 9001, and ISO 13485 management certifications.
The company has a presence in the U.S. and around the world. The company has worldwide distribution through a network of exclusive distributors, agents, and eight subsidiaries in Australia, Canada, China, France, Germany, Japan, Singapore, and the U.K.
Founded in 2005 and headquartered in New York, U.S., Epigentek Group Inc. is engaged in developing, manufacturing, and providing a comprehensive portfolio of proprietary products to provide solutions for epigenetics-related research and drug discovery. The company provides antibodies, research kits, protein enzymes, peptides, and instruments. The company offers these products to esteemed academia, leading pharmaceuticals, and cutting-edge biotechnology companies.
The company products are sold through the sales force and a global network of distributors in more than thirty-six countries and regions: North America, Europe, Asia, South America, the Middle East, and South Pacific. The company was awarded a bronze medal from EcoVadis in recognition of its commitment to sustainability and ethics. Also, the company is rated in the top 23% of the life sciences industry.
Popular Mention : Active Motif (U.S.), Zymo Research Corporation (U.S.), Promega Corporation (U.S.), EPICYPHER (U.S.), Everon Life Sciences (India), GenomeScan (Netherlands), Creative Biogene (U.S.), Nanjing Vazyme Biotech Co., Ltd. (China), BPS Bioscience, Inc. (U.S.), Boca Scientific Inc. (U.S.), Methyl Detect ApS (Denmark), and Enzo Life Sciences, Inc. (U.S.).
Authoritative Research on the Epigenetics Market – Global Opportunity Analysis and Industry Forecast (2024-2031)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
